This scoping review explores the impact of genetic polymorphisms on the pharmacokinetics and treatment responses of mycophenolic acid (MPA), an immunosuppressant. The study includes 83 articles from 1226 original studies, focusing on transplantation (n = 80) and autoimmune disorders (n = 3). Genetic variants in uridine 5'-diphospho-glucuronosyltransferase ( and ) and transmembrane transporters ( and ) significantly affected MPA's pharmacokinetics and susceptibility to its adverse effect. Whereas variants in several genes including , , and have been associated with a higher risk of transplant rejection. However, there is a lack of studies on MPA's impact on autoimmune disorders and limited research on the Asian population. The findings underscore the need for further research on MPA's impact across different populations and diseases, particularly among other Asian ethnic groups, to advance personalized medicine in MPA therapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11388138 | PMC |
http://dx.doi.org/10.1080/14622416.2024.2344430 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!